Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis

Hepatology

Volumn 62, Issue 4, 2015, Pages 1285-1297

  Jiménez Calvente, Carolina ^a   Sehgal, Alfica ^b   Popov, Yury ^c   Kim, Yong Ook ^a   Zevallos, Victor ^a   Sahin, Ugur ^a,d   Diken, Mustafa ^a,d   Schuppan, Detlef ^a,c  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b ALNYLAM PHARMACEUTICALS   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Center of Translational Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; MESSENGER RNA; NANOPARTICLE; PROCOLLAGEN; PROCOLLAGEN ALPHA1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; COLLAGEN TYPE 1; COLLAGEN TYPE I, ALPHA 1 CHAIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIARY TRACT FIBROSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; FIBROGENESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; INNATE IMMUNITY; LIVER FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; ANIMAL; C57BL MOUSE; GENETICS; LIVER CIRRHOSIS; MALE; RNAI THERAPEUTICS;

ANIMALS; COLLAGEN TYPE I; DRUG DELIVERY SYSTEMS; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; RNA, SMALL INTERFERING; RNAI THERAPEUTICS;

EID: 84942551559     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27936     Document Type: Article

References (30)

1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-1669.
2. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001;21:351-372.
3. Sibley CR, Seow Y, Wood MJA. Novel RNA-based strategies for therapeutic gene silencing. Mol Ther 2010;18:466-476.
4. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007;117:3623-3632.
5. Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 2010;107:1864-1869.
6. Novobrantseva TI, Borodovsky A, Wong J, Klebanov B, Zafari M, Yucius K, et al. Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells. Mol Ther 2012;1:e4.
7. Sato Y, Murase K, Kato J, Kobune M, Sato T. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperon. Nat Biotechnol 2008;26:431-442.
8. Akinc A, Goldberg M, Qin J, Dorkin JR, Gamba-Vitalo C, Maier M, et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 2009;17:872-879.
9. Sauk JJ, Nikitakis N, Siavash H. HSP47 a novel collagen binding serpin chaperon, autoantigen and therapeutic target. Front Biosci 2005;10:107-118.
10. Blomhoff R, Green MH, Green JB, Berg T, Norum KR. Vitamin A metabolism: new perspectives on absorption, transport, and storage. Physiol Rev 1991;71:951-990.
11. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013;5:167sr1.
12. 4-induced stomach and duodenum damage and the protective effect of Nigella sativa in adult Wistar rats. IOSR Journal of Dental and Medical Sciences 2014;13:53-58.
13. Gineyts E, Cloos PAC, Borel O, Grimaud L, Delmas PD, Garnero P, et al. Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover. Biochem J 2000;345:481-485.
14. Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sägesser H, et al. Pharmacological inhibition of integrin aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009;50:1501-1511.
15. Wells RG. The role of matrix stiffness in regulating cell behavior. Hepatology 2008;47:1394-1400.
16. Qamar A, Sheikh SZ, Masud A, Jhandier MN, Inayat IB, Hakim W, et al. In vitro and in vivo protection of stellate cells from apoptosis by leptin. Dig Dis Sci 2006;51:1697-1705.
17. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318.
18. Moghimi SM, Porter CJH, Muir IS, Illum L, Davis SS. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun 1991;177:861-866.
19. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2010;2:14.
20. Jiang JX, Chen X, Hsu DK, Baghy K, Serizawa N, Scott F, et al. Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo. Am J Physiol Gastrointest Liver Physiol 2012;302:G439-G446.
21. Pulavendran S, Rose C, Mandal AB. Hepatocyte growth factor incorporated chitosan nanoparticles augment the differentiation of stem cell into hepatocytes for the recovery of liver cirrhosis in mice. J Nanobiotechnol 2011;9:15.
22. Rahman YE, Cerny EA, Patel KR, Lau EH, Wright BJ. Differential uptake of liposomes varying in size and lipid composition by parenchymal and Kupffer cells from mouse liver. Life Sci 1982;31:2061-2071.
23. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002;54:631-651.
24. Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse C, et al. Regulation of Hsp27 oligomerization, chaperone function and protective activity against oxidative stress/tumor necrosis factor α phosphorylation. J Biol Chem 1999;274:18947-18956.
25. Akinc A, Bettencourt B, Maier M. Development of RNAi therapeutics. In: Templeton NS, ed. Gene and Cell Therapy: Therapeutic Mechanisms and Strategies. 4th ed. Boca Raton, FL: CRC Press; 2014:493-520.
26. Erwei S, Lee SK. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347-351.
27. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818.
28. Popov Y, Sverdlov DY, Bhaskar KR, Sharma AK, Millonig G, Patsenker E, et al. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol 2010;298:G323-G334.
29. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005;23:165-175.
30. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005:23:457-462.